IMS CORE lab teams up with Cristal Therapeutics
Cristal Therapeutics has announced that it has secured a Horizon 2020 grant. This allows the company to further develop the CriPec Nanomedicine Platform. This will be done in collaboration with the IMS CORE lab at Maastricht University’s M4I Division of Imaging Mass Spectrometry.
Cristal Therapeutics is a phase 2 clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases. The ICARUS project will be carried out in close collaboration with the IMS CORE lab at the division of Imaging Mass Spectrometry, where CriPec® nanoparticle microlocalisation and drug release in tumours will be evaluated. Mass spectrometry imaging, technology together with Cristal Therapeutics’ expert team, will provide critical new insights to optimally design CriPec® nanomedicines with the aim of achieve superior therapeutic profiles.
The project at M4I will be led by Dr. Berta Cillero Pastor and by Prof. Ron Heeren.
For more details, read the full article on the Cristal Therapeutics website: http://cristaltherapeutics.com/cristal-therapeutics-awarded-horizon-2020-grant-to-further-develop-the-cripec-nanomedicine-platform/
How is the EU responding to the evolving landscape of consumer law in the face of digitalization and climate crisis? On 6 February 2024, the Globalization & Law Network had the privilege to discuss these issues with Dr. Vanessa Mak, Professor of Civil Law at Leiden University.
PhD thesis written by Andrés Horacio Cáceres-Solari
The research argues the incompatibility of the principle of distinction as codified/internationally interpreted in modern insurgency warfare. It argues that current IHL is narrow in scope to regulate modern insurgency warfare, establishes...
Dr. Fred Spoor, an expert on human evolution affiliated with the Natural History Museum, London, has been appointed as the Eugène Dubois chair for the year 2024.